| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -28.7 | -26.7 |
| Net income | -28.8 | -26.7 |
| EPS (diluted, $ a share) | $-0.34 | $-0.37 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: ZNTL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Zentalis Pharmaceuticals, Inc.: key numbers
- Share price
- $1.49Close, Nov 17
- Market cap
- $146M
- Shares outstanding
- 98.27MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Zentalis Pharmaceuticals, Inc.
All →Zentalis Pharmaceuticals Financial Results
Zentalis Pharmaceuticals reported third quarter 2026 financial results and provided updates on its clinical pipeline, specifically the azenosertib program for ovarian cancer. The company expects a topline readout from the DENALI trial in the first half of 2027 and reported a cash runway extending into the first half of 2028.
“Overall survival data from DENALI Part 1b presented at ESMO reinforce our confidence in azenosertib to offer a differentiated oral treatment for patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC), if approved.”
Julie Eastland, Chief Executive Officer of Zentalis Pharmaceuticals
“With $228.9 million on the balance sheet providing an anticipated runway into the first half of 2028, we believe we are well resourced to support key DENALI milestones, full enrollment in ASPENOVA and combination trials in ovarian cancer and triple-negative breast cancer.”
Julie Eastland, Chief Executive Officer of Zentalis Pharmaceuticals